Join the EURIPID Workshop at the PPRI Conference

/in /by

The WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, located at Gesundheit Österreich GmbH (GÖG/Austrian National Public Health Institute) in Vienna organise this year 5th PPRI Conference. From Thursday, 25 April till Friday 26 April Health experts will discuss at the Palais Niederösterreich in Vienna about „Ensuring access to affordable medicines through innovative policies“. The EURIPID Collaboration has been invited to organise a conference workshop on Friday, and we are very pleased to anounce that we have developed a very interesting session titled „How the Euripid collaboration contributes to improving access to biosimilars“.

Biosimilars have an efficacy and safety so similar that they are considered interchangeable with their reference medicines. They hold the potential to contribute to the financial sustainability of health care systems and improve access to medicines for patients. Despite their advantages, barriers remain and to a certain extent impede their successful entry into the market or uptake by health systems. During the workshop experts will explore reasons for those barriers and dicuss potential solutions.

Here is the programme for the EURIPID Conference workshop on Friday, 26 April 2024, 13.30 – 15.00

  • Welcoming by the Chair of the Session Claudia Habl, Austrian National Public Health Institute, Secratary of the Board of Participants (BoP) of EURIPID
  • Introduction of EURIPID and current EC Grant by Gergely Németh (Semmelweis University, Hungarian National Health Insurance Fund, project manger of EURIPID)
  • Keynote: „Impact of market entries of biosimilars in Slovenia“ by Matjaž Marc, Agency for Medicinal Products and Medical Devices of the Slovenian Republic (JAZMP, tbc)
  • Plenary Discussion on „Biosimilars – Monitoring & policies in the product life cycle management“ moderated by the chair of the session; Speakers at the panel are (in alphabetical order)
    • Francis ARICKX, National Institute for Health and Disability Insurance (RIZIV-INAMI)
    • Liese BARBIER, Katholieke Universiteit Leuven, European Mediciens Agency (EMA)
    • Dorthe BARTHELS, AMGROS
    • Magnus BODIN, Medicines for Europe
  • Open questions to panelists from the audiences
  • Wrap-up by the chair of the session

The EURIPID collaboration hopes to welcome many interested participants at the workshop.